Stock exchanges

Stock exchanges

Immuneering Corporation Announces Interim Data from Phase 2a Clinical Trial of Atebimetinib in Pancreatic Cancer Patients

Immuneering Corporation, a biotechnology company, has announced interim data from its ongoing Phase 2a clinical trial evaluating atebimetinib, a once-daily oral MEK inhibitor, in combination with modified Gemcitabine/nab-Paclitaxel (mGnP) in first-line pancreatic cancer patients. As of May 26, 2025, of the 36 response evaluable patients in the mGnP arm,